Research programme: autologous stromal vascular cell therapy - Invigorcell
Latest Information Update: 28 Feb 2019
Price :
$50 *
At a glance
- Originator Invigorcell
- Developer IntelliCell BioSciences
- Class Cell therapies
- Mechanism of Action Cell replacements; Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Diabetes-mellitus in USA (Parenteral)
- 27 Jan 2015 Invigorcell in-licenses technology of producing vascular fraction cells from Intellicell Biosciences
- 27 Jan 2015 Early research in Diabetes mellitus in USA (Parenteral)